3F80.F Q-linea AB (publ)
- Market cap
- EUR 23.5M
- P/E
- -
- P/B
- 0.10x
- ROE
- -50.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 3F80.F undervalued?
Graham numberThe Graham number of Q-linea AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Q-linea AB (publ) fundamental analysis
No fundamental analysis for Q-linea AB (publ) yet.
Q-linea AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Q-linea AB (publ)
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the…
Full company profileQ-linea AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Q-linea AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 9.34M | 12.8M | 4.44M | 2.36M | 11.1M | 11.1M |
| Gross Profit | -25.0M | -21.4M | 995K | -11.1M | -1.69M | 5.30M |
| Operating Income | -232M | -263M | -231M | -214M | -176M | -132M |
| EBITDA | - | -253M | -211M | -196M | -161M | -109M |
| Net Income | -231M | -269M | -229M | -217M | -182M | -124M |
| EPS | -1,121 | -1,302 | -278 | -263 | -9.63 | -6.53 |
| Balance Sheet | ||||||
| Total Assets | 484M | 230M | 232M | 148M | 370M | 277M |
| Total Liabilities | 54.0M | 66.7M | 42.3M | 175M | 31.7M | 31.4M |
| Shareholders' Equity | 430M | 163M | 190M | -27.5M | 338M | 245M |
| Cash & Short-term Investments | 15.1M | 72.9M | 81.9M | 25.7M | 258M | 65.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -249M | -251M | -229M | -182M | -162M | -126M |
| Capital Expenditure | 12.1M | 17.2M | 8.34M | 4.99M | 7.56M | 3.14M |
| Free Cash Flow | -261M | -268M | -237M | -187M | -170M | -129M |
| Ratios | ||||||
| ROE | -53.8% | -164.7% | -121.0% | - | -54.0% | -50.5% |
| ROA | -47.8% | -116.9% | -98.9% | -146.5% | -49.4% | -44.8% |
| Net Profit Margin | -2,479.2% | -2,101.1% | -5,165.9% | -9,181.7% | -1,644.3% | -1,115.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Q-linea AB (publ) dividends
Q-linea AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:1000 on Jul 14, 2025.
Who owns Q-linea AB (publ)
- Insiders 12.89%
- Institutions 27.37%
- Public & others 59.74%
- Shares outstanding 18.9M
- Free float 11.6M
Q-linea AB (publ) company profile
- Company name
- Q-linea AB (publ)
- Ticker
- 3F80.F
- ISIN
- SE0025420714
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 66
- Fiscal year end
- December
- Address
- Dag Hammarskjölds väg 52 A, Uppsala, Sweden, 752 37
- Phone
- 46 18 444 3610
- Website
- qlinea.com
About Q-linea AB (publ)
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Q-linea AB (publ) management
7- Mr. Stuart GanderMD, President & CEO · born 1978
- Ms. Annika Blondeau HenrikssonCFO & IR · born 1969
- Mr. Henrik JacobsonChief Operating Officer · born 1969
- Ms. Natalie BrownDirector of Global Marketing · born 1986
- Ms. Ulrika StolpeHR Manager · born 1967
- Mr. Anders LjunggrenMD & Deputy CEO · born 1981
- Ms. Victoria LernerydManager of QA/RA · born 1984